CXCL12 and CXCR4 as Potential Early Biomarkers for Luminal A and Luminal B Subtypes of Breast Cancer.
Joanna MotykaEwa GacutaAleksandra KicmanMonika KuleszaPaweł MalinowskiSławomir ŁawickiPublished in: Cancer management and research (2023)
The results indicate the preliminary usefulness of CXCL12 and CXCR4 as early biomarkers in the diagnosis of breast cancer, especially in the combined panel with CA 15-3.